A reminder for STEM students considering internships and commercial roles! Chiasma Dunedin's Synapse is set for 6:30pm this Thurs 25 Jul at the Union Hall on Campus. With a guest panel and expo style showcase, it's a great opportunity to learn from others who have made the transition. Read more: https://hubs.ly/Q02Hy9rl0 As with previous years, Pacific Edge are proud to sponsor the event and we'll be running a booth to answer all your questions. Joseph and Mia, two previous interns who have now made the transition to full time roles, will be participating in the panel discussion.
Pacific Edge Ltd
Biotechnology
Dunedin, Otago 2,677 followers
Specialists in the discovery of diagnostic and prognostic tests for the better detection and management of cancer.
About us
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialisation of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA. Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been used by over 4,400 US urologists in the diagnosis and management of more than 100,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 75% of the population via public healthcare and all residents have the option of buying the test online. Learn more at: www.cxbladder.com
- Website
-
http://www.pacificedgedx.com
External link for Pacific Edge Ltd
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Dunedin, Otago
- Type
- Public Company
- Founded
- 2001
- Specialties
- cancer diagnostics, genomic urine testing, bladder cancer diagnostics, molecular diagnostics, cancer prognostics, and commercialisation
Locations
-
Primary
Get directions
Centre for Innovation
87 St David Street
Dunedin, Otago 9016, NZ
-
Get directions
Hershey Center for Applied Research
1214 Research Boulevard, Suite 2000
Hummelstown, PA 17036, US
-
Get directions
Centre for Innovation
87 St David Street
Dunedin, Otago 9016, NZ
Employees at Pacific Edge Ltd
Updates
-
Cxbladder Monitor is a non-invasive genomic urine test that can reduce the frequency of cystoscopy required in those being monitored for recurrent non-muscle invasive bladder cancer. Learn more about the survey and the test: https://hubs.ly/Q02H05Bp0 #StayOnTrack || Bladder Cancer Advocacy Network
-
-
Bridging the Gap in Microhematuria Evaluation: Dr Yair Lotan and Pacific Edge Chief Medical Officer Dr Tamer Aboushwareb discuss the STRATA study, a randomized controlled trial showing Cxbladder Triage can more effectively risk stratify microhematuria patients vs AUA guidelines: https://hubs.ly/Q02GQ-t30 (via UroToday + GU OncToday)
-
-
Calling all aspiring scientists! Chiasma Dunedin's Synapse event is being held Thurs 25 July. Synapse will feature a keynote speaker alongside a guest panel and expo-style showcase. It's a great opportunity to learn from others who have made the transition from academia into a commercial role. Read more: https://hubs.ly/Q02GGtM10
-
-
Q1 25 Investor Update: Pacific Edge today announces tests processed at its laboratories in the three months to the end of June 2024 were steady on the prior quarter (Q4 24). Learn more: https://hubs.ly/Q02FY8r60
-
-
Cxbladder Monitor is a genomic urine test that can help ease the burden of invasive testing, reducing the frequency of cystoscopy required in those being monitored for recurrent non-muscle invasive bladder cancer. Read more: https://hubs.ly/Q02F9gnb0 #StayOnTrack || Bladder Cancer Advocacy Network
-
-
News to share! Pacific Edge is pleased to present its Annual Report for the year ended 31 March 2024. Review the Report: https://hubs.ly/Q02Dv-F90
-
-
News to share! Results from the STRATA Randomized Controlled Trial headline Urology Times: "Urinary genomic test demonstrates utility in cystoscopy decision-making - Patients in the Cxbladder arm had a 59% relative reduction in the number of cystoscopies performed vs those in the control arm." Review the article: https://hubs.ly/Q02CyhTz0
-
-
Bridging the Gap in Microhematuria Evaluation: Dr Yair Lotan and Pacific Edge Chief Medical Officer Dr Tamer Aboushwareb discuss the STRATA study, a randomized controlled trial showing Cxbladder Triage can more effectively risk stratify microhematuria patients vs AUA guidelines: https://hubs.ly/Q02Clc_Q0 (via UroToday + GU OncToday)
-
-
In December 2023, working with the Bladder Cancer Advocacy Network we surveyed 1,507 US patients being monitored for recurrent non-muscle invasive bladder cancer using the BCAN Patient Survey Network. Those surveyed reported a strong interest in non-invasive test options. Learn more: https://hubs.ly/Q02BrVJb0 #StayOnTrack